Historically this has been managed by platelet transfusions, but this has certain limitations.[2,5,9] It is also important to note that the primary causes of thrombocytopenia in CLD are splenic platelet sequestration and breakdown, and decreased production of thrombopoietin in the liver,[2,4] and therefore administering steroid treatment (the first-line treatment for immune thrombocytopenia)[12,13] is inappropriate. The gene discussed is THPO; the disease is autoimmune thrombocytopenic purpura.